This is the first report of a phase I study with zzso zzso zzso 2 shows a higher biological activity and different zzso effects compared to zzso zzso zzso 14 patients (9 male, 5 zzso entered our phase I study with continuous zzso zzso 2 with a median age of 40 years zzso zzso including 4 zzso The study design was a dose rising continuous zzso infusion over 5 days with a starting dose of 1 zzso zzso U zzso 2 up to 6 zzso zzso zzso 2 over 24 zzso In 2 of 16 regimen with zzso zzso there was a dose reduction and in 6 there was an interruption zzso In 2 patients there was only a dose reduction necessary because of zzso and zzso In 6 patients zzso 2 had to break the continuous zzso zzso were an increasing zzso respiratory zzso zzso neurological symptoms and increasing liver zzso The 4 children developed an other side effect profile with zzso of the face, abdominal zzso and zzso During the study no intensive care was zzso The most common side effects were zzso fever, zzso zzso and zzso There was no complete zzso zzso of the patients had a partial zzso zzso showed no change and zzso had a zzso There were no significant differences in toxicity and response was comparable to studies using continuous r zzso 
